AstraZeneca
Strong showing for AZ asthma drug, but diabetes treatment flops
May 23, 2017Manufacturing and Production, Research and Development AstraZeneca, asthma, diabetes
AstraZeneca has been mulling over mixed news this week after both its severe asthma treatment and diabetes therapy saw varying …
AstraZeneca sells off rights to beta-blocker for $300 million
May 22, 2017Sales and Marketing AstraZeneca, Recordati, Seloken
AstraZeneca announced that it had sold the European rights to its drug, Seloken (metoprolol), to Italian pharmaceutical company Recordati. The …
AZ launches lawsuit against former executive for defecting to GSK
May 17, 2017Manufacturing and Production, Research and Development AZ, AstraZeneca, GSK, GlaxoSmithKline
AstraZeneca has launched a lawsuit against one of its former executives after he jumped ship to join rival pharma giant …
AZ asthma drug falls short in Phase 3 study
May 10, 2017Research and Development AstraZeneca, asthma, tralokinumab
AstraZeneca and its global biologics research and development arm MedImmune have announced that asthma treatment tralokinumab has failed to achieve …
Potential blockbuster AZ immunotherapy secures FDA approval
May 2, 2017Manufacturing and Production, Sales and Marketing AstraZeneca, bladder cancer, darzalex
The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi (durvalumab) for the treatment of locally advanced or …
AZ’s Tagrisso continues successes with EU approval
April 26, 2017Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso
More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …
AbbVie’s experimental cancer drug hits wall in clinical study
April 20, 2017Research and Development AbbVie, AstraZeneca
AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary endpoints. …
AstraZeneca ends month with two pieces of news
March 31, 2017Medical Communications, Sales and Marketing AstraZeneca, Tagrisso, TerSera Therapeutics, Zoladex
AstraZeneca has ended the month with more positive news on Tagrisso, that had previously been approved in China under its …
AstraZeneca’s medicine approved under China’s Priority Review
March 27, 2017Sales and Marketing AstraZeneca, Tagrisso, lung cancer
AstraZeneca has been boosted by the news that its drug, Tagrisso, has become its first drug to be approved under …
AstraZeneca hit with second blow on $2.7 billion drug
March 17, 2017Medical Communications AstraZeneca, FDA, hyperkalaemia
AstraZeneca paid $2.7 billion for ZS Pharma, back in 2015, with the desire to get its hands on the company’s …
FDA green lights AstraZeneca type-2 diabetes drug
February 28, 2017Manufacturing and Production, Sales and Marketing AstraZeneca, FDA
AstraZeneca has announced that its type-2 diabetes treatment Qtern (10mg dapagliflozin and 5mg saxagliptin) has received the approval of the …
AstraZeneca’s hyperkalaemia treatment rebounds with European recommendation
February 24, 2017Sales and Marketing AstraZeneca, EMA
AstraZeneca have received some positive news on its hyperkalaemia drug, ZS-9, as it received a recommendation from the Committee for …
India’s NPPA identifies 634 non-compliant drug pricings
February 24, 2017Medical Communications, Sales and Marketing Abbott, AstraZeneca, Cipla, Dr Reddy's, Dr Reddy’s, nppa
India’s National Pharmaceutical Pricing Authority (NPPA) has revealed that as many as 634 drugs from top pharma firms in the …
China’s insurance expansion boon to global pharma
February 23, 2017Sales and Marketing AstraZeneca, China, GSK, Shire
China has expanded the list of medicines that are covered on basic medical insurance schemes, named China’s National Reimbursement Drug …
AstraZeneca sells off cancer drug to TerSera for $250 million
February 20, 2017Sales and Marketing AstraZeneca, TerSera Therapeutics, Zoladex
AstraZeneca announced that it has sold Zoladex’s (goserelin acetate implant) commercial rights in the US and Canada to TerSera Therapeutics. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
